Management of Iron Overload in the Canadian Hematology/oncology Population: Implications for Nursing Practice

Overview

Journal Can Oncol Nurs J

Date 2019 Jun 1

PMID 31148725

Authors

Cindy Murray

Tammy De Gelder

Nancy Pringle

J Colleen Johnson

Mary Doherty

Affiliations

Soon will be listed here.

Abstract

Red blood cell (RBC) transfusions are vital for many patients with chronic anemias associated with oncologic/hematologic disorders. However, repeated transfusions over time can lead to iron overload, which, if left untreated, can increase the risk of further malignancy and end-organ damage. Nurses and other health care professionals may not be aware of the significant implications of RBC transfusions and iron overload in patients with hematological/oncological disorders. This article was developed by a group of Canadian nurse practitioners and specialized oncology nurses to help improve health care professionals' understanding of iron overload in oncology patients and its associated risks, as well as provide a practical guide for the management of patients receiving treatment for this potentially serious condition.

References

Steensma D . The relevance of iron overload and the appropriateness of iron chelation therapy for patients with myelodysplastic syndromes: a dialogue and debate. Curr Hematol Malig Rep. 2011; 6(2):136-44. DOI: 10.1007/s11899-011-0084-z. View

Ibrahim A, Gebremariam T, Luo G, Fu Y, French S, Edwards Jr J . Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins. Antimicrob Agents Chemother. 2011; 55(4):1768-70. PMC: 3067166. DOI: 10.1128/AAC.01577-10. View

Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini M, Del Vecchio G . Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004; 89(10):1187-93. View

Pullarkat V, Blanchard S, Tegtmeier B, Dagis A, Patane K, Ito J . Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2008; 42(12):799-805. DOI: 10.1038/bmt.2008.262. View

Gabutti V, Piga A . Results of long-term iron-chelating therapy. Acta Haematol. 1996; 95(1):26-36. DOI: 10.1159/000203853. View

Pullarkat V . Iron overload in patients undergoing hematopoietic stem cell transplantation. Adv Hematol. 2010; 2010. PMC: 2943091. DOI: 10.1155/2010/345756. View

Cappellini M . Overcoming the challenge of patient compliance with iron chelation therapy. Semin Hematol. 2005; 42(2 Suppl 1):S19-21. DOI: 10.1053/j.seminhematol.2005.01.001. View

Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M . Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007; 78(6):487-94. DOI: 10.1111/j.1600-0609.2007.00842.x. View

Bring P, Partovi N, Ford J, Yoshida E . Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy. Pharmacotherapy. 2008; 28(3):331-42. DOI: 10.1592/phco.28.3.331. View

10.

Goldberg S, Giardina P, Chirnomas D, Esposito J, Paley C, Vichinsky E . The palatability and tolerability of deferasirox taken with different beverages or foods. Pediatr Blood Cancer. 2013; 60(9):1507-12. DOI: 10.1002/pbc.24561. View

11.

List A . Iron overload in myelodysplastic syndromes: diagnosis and management. Cancer Control. 2010; 17 Suppl:2-8. DOI: 10.1177/107327481001701s01. View

12.

Fenaux P, Mufti G, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A . Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009; 10(3):223-32. PMC: 4086808. DOI: 10.1016/S1470-2045(09)70003-8. View

13.

Wells R, Leber B, Buckstein R, Lipton J, Hasegawa W, Grewal K . Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk Res. 2008; 32(9):1338-53. DOI: 10.1016/j.leukres.2008.02.021. View

14.

Meyer S, OMeara A, Buser A, Tichelli A, Passweg J, Stern M . Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2012; 19(3):440-4. DOI: 10.1016/j.bbmt.2012.10.012. View

15.

Zurlo M, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C . Survival and causes of death in thalassaemia major. Lancet. 1989; 2(8653):27-30. DOI: 10.1016/s0140-6736(89)90264-x. View

16.

Stein J, Hartmann F, Dignass A . Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010; 7(11):599-610. DOI: 10.1038/nrgastro.2010.151. View

17.

Carson S, Martin M . Effective iron chelation practice for patients with β-thalassemia major. Clin J Oncol Nurs. 2014; 18(1):102-11. DOI: 10.1188/14.CJON.102-111. View

18.

Taher A, Al Jefri A, Elalfy M, Al Zir K, Daar S, Rofail D . Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial. Acta Haematol. 2010; 123(4):220-5. DOI: 10.1159/000313447. View

19.

Shah J, Kurtin S, Arnold L, Lindroos-Kolqvist P, Tinsley S . Management of transfusion-related iron overload in patients with myelodysplastic syndromes. Clin J Oncol Nurs. 2012; 16 Suppl:37-46. DOI: 10.1188/12.CJON.S1.37-46. View

20.

Leitch H . Controversies surrounding iron chelation therapy for MDS. Blood Rev. 2010; 25(1):17-31. DOI: 10.1016/j.blre.2010.09.003. View